PID treatment




A recent study suggested that we should be adding metronidazole to the treatment of acute pelvic inflammatory disease (see PID rx include metronid clinifndz2020 in dropbox, or doi.org/10.1093/cid/ciaa101 )

Details:
-- 233 women 14-50 years old were enrolled based on the following clinical criteria for acute PID: pelvic or lower abdominal pain, and the presence of cervical motion tenderness, uterine tenderness, or adrenal tenderness on pelvic exam. Those requiring inpatient hospitalization or who were pregnant were excluded. From 2010-2015.
-- Median age 23, 59% black/28% white, 51% current smokers, 75% ever pregnant, 14% had IUD, pelvic pain duration at least 3 days in 78%, pelvic pain severity 60 mm (visual analog scale of 0-100 mm), clinical tenderness score 9.9
-- history of chlamydia was 60%, gonorrhea 27%, PID 29%
-- women received an IM injection of ceftriaxone 250mg plus doxycycline 100 mg twice daily for 14 days, with or without metronidazole 500 mg twice daily for 14 days
-- assessment was done 3 days later, including a pelvic exam; another evaluation at 30 days, including a pelvic exam along with vaginal endocervical swabs and endometrial sampling
-- primary outcome was clinical improvement at the 3 day follow-up visit
-- secondary outcome was clinical cure at 30 days (>70% improvement in clinical tenderness score and absence of fever), as well as the presence of anaerobic organisms in the endometrium at 30 days
-- medication adherence was defined as taking at least 75% of the metronidazole and doxycycline doses

Results:
-- at 3-day visit, comparing those on metronidazole vs placebo:
    -- clinical improvement: 83% vs 80% in intention-to-treat, 92% vs 90% per-protocol analysis
    -- pelvic pain: 39% vs 38%, with decrease from enrollment of 40% vs 42%
    -- clinical tenderness score 3.4 vs 3.1, with decrease from enrollment of 6.6 vs 6.8 [tenderness score max of 12, with up to 3 points for each or right and left adnexae tenderness, cervical motion tenderness, and uterine tenderness]
-- at the 30 day visit, comparing metronidazole vs placebo:
    -- clinical cure 97% vs 90%
    -- pelvic pain 9% vs 12%
    -- pelvic pain severity 4 vs 4.2, with difference from enrollment being 59% vs 57%
    -- pelvic tenderness 9% vs 20% (this is the only one reaching statistical significant, at p=0.037)
-- cervical microorganisms before and 30 days after treatment, comparing metronidazole vs placebo:
    -- chlamydia: 16%, decreasing to 1% vs 14% decreasing to 1%
    -- gonorrhea: 5% decreasing to 3% vs 9% decreasing to 3%
    -- M. genitalium: 15% decreasing to 4% vs 21% decreasing to 14% (statistically significant at p=0.039)
    -- trichomonas: 8% decreasing to 5% vs 9% increasing to 12%
    -- bacterial vaginosis: 56% decreasing to 21% vs 53% increasing to 54%, p<0.001
-- endometrial microorganisms before and 30 days after treatment, comparing metronidazole vs placebo:
    -- chlamydia: 10% decreasing to zero vs 10% decreasing to 1%
    -- gonorrhea: 5% decreasing to zero vs 5% decreasing to zero
    -- M. genitalium: 6% decreasing to 1% vs 9% decreasing to 4%
    -- H. influenzae: 1% decreasing to zero vs 4% decreasing to 2%
    -- G vaginalis: 21% decreasing to 12% vs 27% increasing to 33%, p=0.001
    -- A. vaginae: 11% decreasing to 2% vs 11% increasing to 14%, p=0.006
    -- anaerobic gram-negative rods: 10% decreasing to 5% vs 9% increasing to 12%
    -- anaerobic positive cocci: 10% decreasing to 7% vs 10% increasing to 11%
    -- combo of A. vaginae and/or anaerobic gram-negative rods and/or anaerobic gram-positive cocci: decreasing from 17% to 8% vs increasing from 19% to 21%, p=0.02
-- adverse events: comparing metronidazole vs placebo, none statistically significant:
    -- overall 90% vs 80% had at least one adverse event
    -- most common GI: 80% vs 74%, mostly nausea at 50% vs 47%, vomiting at 35% vs 32%, diarrhea at 36% vs 30%
    -- GU: 47% vs 41%, vulvovaginal candidiasis 16% vs 6% genital irritation 11% vs 4%
    -- overall, grade 1: 83% vs 74%, grade 2: 46% vs 39%, grade 3 (serious): 5% vs 3%, almost all related to hospitalization for inpatient treatment
  
Commentary:
-- the CDC recommends intramuscular cephalosporin (e.g. ceftriaxone 250 mg IMx1 dose) plus doxycycline 100 mg twice daily for 14 days, though this regimen has limited efficacy against anaerobes (and this regimen was largely designed for management of gonorrhea and chlamydia)
    -- the relative role of chlamydia and gonorrhea in acute PID seems to have declined over time, with studies suggesting between 11-55% are caused by these organisms. The above study confirmed that only 22% were associated with clinical diagnosis of acute PID
-- the European guidelines from 2018 recommend the addition of metronidazole to cover anaerobes
-- one concern about the addition of metronidazole is its tolerability, though this study does suggest pretty equivalent tolerability with or without it
-- of note in the above study, though pelvic pain was similar between the two groups, pelvic organ tenderness was found in 9% of women on metronidazole vs 20% on placebo, with p<0.05. This is concerning since persistent inflammation may well be related to higher levels of subsequent chronic pelvic pain and infertility/tubal pregnancies
-- clinical cure rates were similar between the two groups, but notably cervical infection with M genitalium following treatment was significantly less in those on metronidazole, despite the fact that metronidazole has no activity against this organism (this metronidazole benefit has been seen in another study as well). This suggests that there is either a symbiotic relationship between anaerobic species susceptible to metronidazole and M genitalium, or that some combination of antibiotics exceeds their individual effectiveness in M genitalium (as an example of the latter: treating H Pylori with the sequential administration of amoxacillin prior to clarithromycin leads to H pylori susceptability to clarithromycin-resistant organisms: see http://gmodestmedblogs.blogspot.com/2016/10/h-pylori-regimens-stratified-by.html )
    -- the benefits of metronidazole on M genitalium is particularly significant given the much higher potential morbidity of the more typical treatment with moxifloxacin [though I would not suggest treating M genitalium with metronidazole, but in the setting of acute PID where M genitalium was present and treatment included metronidazole, i would recheck for M genitalium prior to considering further treatment with moxifloxacin or other agents]
    -- the role of M genitalium is most clearly associated with male urethritis, less clear with sexually-transmitted infections in women (see http://gmodestmedblogs.blogspot.com/2019/02/new-test-for-m-genitalium-frequent.html )
-- as expected, there were fewer anaerobic microorganisms present after therapy with metronidazole

-- limitations of the study include the fact that they defined PID by clinical criteria instead of confirming it by laparoscopy (though this is standard clinical practice), and they did not evaluate any of the important long-term outcomes (recurrent PID, infertility, ectopic pregnancy, chronic pain)

So,
-- it was notable that metronidazole did decrease anaerobic infections, M genitalium, and pelvic pain at 30 days, suggesting that there might be lower subsequent incidence of chronic pelvic pain syndromes as well as infertility and ectopic pregnancy (other studies have suggested that endometrial anaerobic organisms are associated with higher rates of endometritis, and this is associated with infertility and chronic pain even if subclinical)
-- there was no significant increase in adverse effects by adding the metronidazole, though it should be noted that the level of adverse effects was pretty astronomical in both groups (though almost all were pretty mild)
-- so, based on this study, it does seem that adding metronidazole may be really beneficial, esp in decreasing potential long-term sequelae of acute PID (eg chronic pelvic pain syndrome, infertility and ectopic pregnancy), as is recommended by other (eg European) guidelines

geoff​

If you would like to be on the regular email list for upcoming blogs, please contact me at gmodest@uphams.org

to get access to all of the blogs:
1. go to http://gmodestmedblogs.blogspot.com/ to see them in reverse chronological order
2. click on 3 parallel lines top left, if you want to see blogs by category, then click on "labels" and choose a category​
3. or you can just click on the magnifying glass on top right, then  type in a name in the search box and get all the blogs with that name in them

please feel free to circulate this to others. also, if you send me their emails, i can add them to the list

Comments

Popular posts from this blog

air pollution and heart disease

UPDATE: ASCVD risk factor critique

visceral fat loss is sustained long-term